Myeloma Minute: Preparing for Summer: The Essentials


Preparing for Summer: The Essentials Summer is finally here. In his blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie discusses the importance of relaxing and de-stressing over the summer months, but also highlights essentials to keep in mind while safely planning for summer activities. He highly recommends paying close attention to COVID-19 community levels in order to devise the best plan, back-up plan, and course of action — especially for those who are traveling. Vaccination, mask-wearing, COVID-19 testing, anti-viral treatment prescriptions, and prudent travel planning are necessities for myeloma patients to ensure their safety.


Video Presentations from Myeloma Experts at ASCO and EHA 2022 Top cancer researchers from across the globe gathered this year for the annual American Society of Clinical Oncology (ASCO) Meeting and European Hematology Association (EHA) Congress. The International Myeloma Foundation (IMF) team is providing these lecture-type video presentations to keep you updated on the latest developments in clinical trials and studies on CAR T-cell therapies, bispecifics, four-drug combination therapies, and more. This is an ongoing event, with more video presentations to be posted. Please check back for updates on the IMF website.


Happening Today: Living Well with Myeloma Webinar Today, June 23, at 7 p.m. ET, the Living Well with Myeloma Webinar will focus on “A Promising Future for Treating Multiple Myeloma with Bispecific Antibodies.” IMF Vice President of Support Groups Robin Tuohy will moderate presentations with the following speakers: Donna Catamero, ANP-BC, OCN, CCRC (The Mount Sinai Health Center—New York, NY, IMF Nurse Leadership Board), and Tom Martin, MD (University of California San Francisco—San Francisco, CA). To ensure patients and care partners better understand the promising future in bispecific therapies, please tune in to this Live Webinar, as guest speakers cover key questions, concerns, and highlights.


This Week: The 2^nd Virtual M-Power Charlotte Webinar The IMF M-Power Initiative is focused on changing the course of myeloma in the African American community. Myeloma is two times as common in people of African descent as it is in all other races and ethnicities. Empower yourself by joining our 2nd virtual M-Power Charlotte webinar on June 25, 10 a.m.–12:30 p.m. ET. Event panelists include Dr. Peter Voorhees (Levine Cancer Institute – Charlotte); Tiffany W. Crank, MPH (Levine Cancer Institute – Charlotte); IMF Nurse Leadership Board member Amy E. Pierre, RN, MSN, ANP-BC; local myeloma patient and advocate, Pastor Robert Pugh; IMF Patient, President & CEO Yelak Biru; and IMF Chief Medical Officer Dr. Joseph Mikhael. Panelists will be participating in real time and answering your questions.


Download Understanding NINLARO® (ixazomib) capsules — 2022 Edition Ninlaro® is the first FDA-approved proteasome inhibitor used in the treatment of myeloma that is taken by mouth in capsule form rather than being administered intravenously. Ninlaro is approved in combination with the immunomodulatory agent Revlimid® (lenalidomide) and the steroid dexamethasone, a three-drug combination known as “IRd,” for the treatment of patients who have received at least one prior therapy. *Get your FREE copy of the IMF’s Understanding NINLARO® (ixazomib) capsules* in printed form or as a downloadable PDF with hyperlinks to informative resources.**


Now Open for Applications: The 2023 Brian D. Novis Research Grants The Brian D. Novis Research Grant was established in 1995 to honor IMF co-founder Brian D. Novis, who succumbed to multiple myeloma in July 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2023 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline for submission of applications is on September 1, 2022.


George and Julia’s 50^th Anniversary Celebration IMF Fundraiser George and Julia will be celebrating their 50th anniversary this coming July. To celebrate this milestone, the couple has collaborated with the International Myeloma Foundation (IMF) to raise money and help find a cure. In lieu of gifts, George and Julia are requesting for donations to the IMF instead. Please show your support by donating through the IMF website.


#ASKDRDURIE \| Dr. Durie's Weekly Web Video Series When should smoldering multiple myeloma patients start treatment?

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Upcoming Events

Donate Now
Laughs 4 Life

Donate Now
Pieces to A Cure Quilt Raffle

Donate Now
Marnie’s 70th Birthday

Webinar Replays

Watch the Replay
Regional Community Workshop — New England

Watch the Replay
IMF Patient & Family Webinar – New Frontiers in Myeloma Care

Watch the Replay
Regional Community Workshop — Midwest

See also, all of our events.

We Thank Our Sponsors:

GSK, Janssen Oncology, Legend Biotech, and Karyopharm Therapeutics

We also thank individuals like you for your continued support!

Join the conversation at The International Myeloma Foundation

Facebook: /Myeloma | Twitter @IMFMyeloma | Instagram @IMFmyeloma

www.myeloma.org

This email was sent by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873

We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Privacy Policy

View as web page